For the millions of adults who have undergone hematopoietic stem-cell transplantation — and the clinicians who monitor them — this case report from one of medicine's most rigorous journals raises an underappreciated red flag: measles is not merely a childhood nuisance but a potentially lethal neurological threat in profoundly immunocompromised individuals. The intersection of rising global measles incidence and a growing population of transplant survivors makes this a timely clinical concern.
Published in the New England Journal of Medicine, the report documents measles inclusion-body encephalitis (MIBE) arising in a recipient of an allogeneic stem-cell transplant. MIBE is a rare but almost universally fatal complication caused by persistent measles virus replication within the central nervous system, distinct from the more commonly discussed subacute sclerosing panencephalitis. Unlike typical measles encephalitis, MIBE can occur weeks to months after exposure without the characteristic rash, making clinical recognition exceptionally difficult. The transplant setting — characterized by prolonged T-cell deficiency and immune reconstitution delays — creates precisely the vulnerability that allows the virus to establish CNS persistence.
This case carries implications that extend well beyond a single patient. Allogeneic transplant recipients typically lose pre-existing vaccine-acquired immunity during conditioning regimens, and revaccination with live-attenuated measles vaccine is contraindicated until immune reconstitution is confirmed, often not until 18–24 months post-transplant. This creates a prolonged immunity gap during which measles exposure carries disproportionate danger. The report underscores a systemic clinical gap: measles is often not on the differential when transplant patients present with encephalopathy, potentially delaying diagnosis and any chance of antiviral intervention. Given measles resurgence in multiple countries, the immunocompromised transplant community represents a silent high-risk cohort that warrants structured exposure-prevention protocols and heightened diagnostic vigilance. Incrementally, this is a confirmatory clinical signal; systemically, it is a call to recalibrate post-transplant infectious disease surveillance.